Logo image of AVXL

ANAVEX LIFE SCIENCES CORP (AVXL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AVXL - US0327973006 - Common Stock

3.67 USD
-0.22 (-5.66%)
Last: 12/19/2025, 8:00:01 PM
3.73 USD
+0.06 (+1.63%)
After Hours: 12/19/2025, 8:00:01 PM
Fundamental Rating

3

AVXL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVXL as it has an excellent financial health rating, but there are worries on the profitability. AVXL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AVXL had negative earnings in the past year.
In the past year AVXL has reported a negative cash flow from operations.
AVXL had negative earnings in each of the past 5 years.
AVXL had a negative operating cash flow in each of the past 5 years.
AVXL Yearly Net Income VS EBIT VS OCF VS FCFAVXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

AVXL has a Return On Assets of -44.67%. This is comparable to the rest of the industry: AVXL outperforms 55.08% of its industry peers.
AVXL has a Return On Equity of -48.89%. This is in the better half of the industry: AVXL outperforms 66.17% of its industry peers.
Industry RankSector Rank
ROA -44.67%
ROE -48.89%
ROIC N/A
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
AVXL Yearly ROA, ROE, ROICAVXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVXL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVXL Yearly Profit, Operating, Gross MarginsAVXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AVXL has more shares outstanding
Compared to 5 years ago, AVXL has more shares outstanding
AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVXL Yearly Shares OutstandingAVXL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AVXL Yearly Total Debt VS Total AssetsAVXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

An Altman-Z score of 16.30 indicates that AVXL is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 16.30, AVXL belongs to the best of the industry, outperforming 86.84% of the companies in the same industry.
AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.3
ROIC/WACCN/A
WACCN/A
AVXL Yearly LT Debt VS Equity VS FCFAVXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 11.60 indicates that AVXL has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.60, AVXL belongs to the best of the industry, outperforming 85.90% of the companies in the same industry.
A Quick Ratio of 11.60 indicates that AVXL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 11.60, AVXL belongs to the top of the industry, outperforming 85.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.6
Quick Ratio 11.6
AVXL Yearly Current Assets VS Current LiabilitesAVXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AVXL have decreased by -3.85% in the last year.
EPS 1Y (TTM)-3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 63.20% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.41%
EPS Next 2Y75.13%
EPS Next 3Y78.26%
EPS Next 5Y63.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVXL Yearly Revenue VS EstimatesAVXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
AVXL Yearly EPS VS EstimatesAVXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVXL. In the last year negative earnings were reported.
Also next year AVXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVXL Price Earnings VS Forward Price EarningsAVXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVXL Per share dataAVXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

AVXL's earnings are expected to grow with 78.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y75.13%
EPS Next 3Y78.26%

More info and screens

0

5. Dividend

5.1 Amount

AVXL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (12/19/2025, 8:00:01 PM)

After market: 3.73 +0.06 (+1.63%)

3.67

-0.22 (-5.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-25 2025-11-25/amc
Earnings (Next)02-10 2026-02-10
Inst Owners37.14%
Inst Owner Change0.92%
Ins Owners3.23%
Ins Owner Change1.47%
Market Cap327.91M
Revenue(TTM)N/A
Net Income(TTM)-46.38M
Analysts80
Price Target22.44 (511.44%)
Short Float %29.08%
Short Ratio9.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.33%
Min EPS beat(2)-9.44%
Max EPS beat(2)28.1%
EPS beat(4)3
Avg EPS beat(4)13.24%
Min EPS beat(4)-9.44%
Max EPS beat(4)28.1%
EPS beat(8)6
Avg EPS beat(8)11.61%
EPS beat(12)10
Avg EPS beat(12)12.78%
EPS beat(16)12
Avg EPS beat(16)10.67%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-35.92%
EPS NQ rev (1m)12%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-136.64%
EPS NY rev (3m)-136.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)16.08%
Revenue NY rev (3m)16.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.46
P/tB 3.46
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.67%
ROE -48.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.6
Quick Ratio 11.6
Altman-Z 16.3
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
EPS Next Y2.41%
EPS Next 2Y75.13%
EPS Next 3Y78.26%
EPS Next 5Y63.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1044.8%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.72%
OCF growth 3YN/A
OCF growth 5YN/A

ANAVEX LIFE SCIENCES CORP / AVXL FAQ

Can you provide the ChartMill fundamental rating for ANAVEX LIFE SCIENCES CORP?

ChartMill assigns a fundamental rating of 3 / 10 to AVXL.


What is the valuation status of ANAVEX LIFE SCIENCES CORP (AVXL) stock?

ChartMill assigns a valuation rating of 1 / 10 to ANAVEX LIFE SCIENCES CORP (AVXL). This can be considered as Overvalued.


What is the profitability of AVXL stock?

ANAVEX LIFE SCIENCES CORP (AVXL) has a profitability rating of 1 / 10.


How financially healthy is ANAVEX LIFE SCIENCES CORP?

The financial health rating of ANAVEX LIFE SCIENCES CORP (AVXL) is 8 / 10.